As we move toward an era of precision medicine, novel biomarkers of disease will enable the identification and personalized treatment of new endotypes. In asthma, fractional exhaled 
in FeNO is driven by an upregulation of inducible nitric oxide synthase (iNOS) by cytokines, which are released as a result of type-2 airway inflammation. Scientific evidence supports using suggesting that it depended upon the context, but I did not give a particularly illuminating answer. I cannot honestly recall whether I finally decided whether I was, at heart, a lumper or a splitter. I did, however, get the job.
In the intervening years, I have considered this question deeply. Lumping has distinct advantages; in clinical settings, it allows guidelines to be constructed and applied. By 'lumping' a group of heterogeneous wheezing disorders of childhood together and applying a diagnostic label of 'asthma,' we have created a condition that is sufficiently common and important to enable research and develop an evidence base for treatment. Moreover, the simplistic approach of combining distinct phenotypes under a single term enables educational strategies to be adopted on a large scale. However, despite a wealth of evidence and the production of high-quality national and international guidelines, asthma control remains poor for most children. The gap between optimal outcomes for children with asthma in research settings and observed outcomes is undoubtedly multifactorial. However, the current strategy of lumping is not serving children with asthma or their families.
Guidelines currently suggest, for the most part, a 'one size fits all' approach with a step-up and step-down scheme that belies the inherent complexity and variation seen between individuals. Precision medicine is a new term that describes an approach for disease treatment and prevention that takes into account individual variability in genes, environment, and life choices. This article critically reviews the role of fractional exhaled nitric oxide (FeNO) and specifically the role of the NIOX VERO Ò in the application of precision medicine to children and adults with asthma.
Compliance with Ethics Guidelines
This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by the author. It is a commissioned, peer-reviewed article specifically aimed at giving details of asthma endotypes and the use of the NIOX VERO device in clinical practice.
ENDOTYPES: EXHALED NITRIC OXIDE AND HOW IT RELATES TO ASTHMA
Initial attempts at subdividing asthma types were dependent upon careful delineation of the observable characteristics and clinical features, the phenotype. Originally, this led to a division between intrinsic and extrinsic asthma. In the last decade, there has been a renewed enthusiasm within the research community to split, or subdivide, the asthma phenotype [5] .
This renewed interest has, to an extent, been the result of increased availability of mathematical modelling to approach the available patient data [6] . This has resulted in a 're-discovery' of work initially conducted in Derby in the late 1950s that identified the importance of sputum eosinophilia in determining treatment response [7, 8] .
Phenotypical analysis is fraught with difficulty. Most biological characteristics or laboratory indices are not dichotomous but continuous; moreover, they are variable over time and influenced by treatment. In an attempt to resolve these difficulties, there has been a shift away from phenotyping to endotyping [9] . An endotype is defined by a distinct functional or pathobiological mechanism. This has led to the identification of new distinct groups of children and adults with asthma. Some examples of how phenotypes may overlap with multiple endotypes in children and adults are given in Table 2 .
The relationship between exhaled nitric oxide (eNO) and asthma is complex. Nitric oxide is produced by nitric oxide synthase (NOS) enzymes and is extremely short lived unlike other biological markers. There are three distinct forms of NOS enzymes: endothelial (eNOS), inducible (iNOS) and neuronal (nNOS). eNO is produced in the lung epithelia as a result of expression of iNOS [10, 11] . The activity of iNOS is highly variable, and the concentration of eNO on the breath is dependent upon many factors including the degree of type-2 airway [3] Poor lung function [3] Atopy [3] High bronchodilator reversibility [4] Elevated urinary leukotrienes [3] Black ethnicity [1] High FeNO [3] ICS inhaled corticosteroids, FeNO fractional exhaled nitric oxide, LTRA leukotriene receptor antagonists inflammation, presence of other atopic diseases, exposure to environmental tobacco smoke and body mass index (Table 3) [ [12] [13] [14] [15] [16] [17] [18] [19] [20] . Despite this apparent heterogeneity, eNO has established itself within clinical guidelines as a useful adjunct in the diagnosis of asthma in children and adults [21] . Moreover, changes over time within an individual can be extremely helpful in determining response to treatment profiles and indirectly confirming adherence patterns [22] . 
Accuracy
This is the deviation of the measured value from a known nominal value, i.e., the certified concentration of a NO reference standard. Two replicate determinations were made at each occasion. For each test occasion the mean NO concentration (M) for each set of replicates and Table 3 Factors known to be associated with fractional exhaled nitric oxide concentrations in children and adults with asthma
Increased FeNO Decreased FeNO
Airway eosinophilia [13] Environmental tobacco smoke exposure [14] Total IgE [15] [16] [17] Neonatal respiratory distress syndrome [16] Ingestion of nitrate rich foods, e.g., lettuce [18] Corticosteroid use [12] Increased environmental pollution [19] Female gender [20] FeNO fractional exhaled nitric oxide, IgE immunoglobulin E there were no substantial differences between replicates within age groups, gender groups or randomization sequences, and the difference was within the technical specifications of the device (Fig. 2) .
Inter-Operator Repeatability
Pooled data from two multi-center, single-visit, The majority of tasks were completed without assistance (75 %); one user required help to create a quality control (QC) user and perform a QC test, and two users needed assistance to handle the exemption at foreseeable misuses and stop exhaling before the analysis time was finished; the observer indicated that only one user actually needed help. Where one was worst imaginable and five were best imaginable, the overall impression was rated between 3 and 4, while ease-of-use and visual impression were rated between 4 and 5.
Are There Improvements over NIOX (Table 4) . 
DATA TO SUPPORT MEASURING FENO IN CLINICAL PRACTICE

Diagnosis
In primary care clinical practice, the monitoring of asthma control is currently focused on evaluating clinical symptoms and lung function parameters. However, GINA guidelines and ATS FeNO guidelines suggest that airway inflammation could be assessed to optimize treatment strategies [11, 32, 33] .
FeNO is used to define and confirm airway allergic and eosinophilic inflammation in patients with asthma [16] . Routine use of FeNO alongside traditional clinical assessments may improve diagnostic accuracy and enables tailored therapeutic regimens [16, 34, 35] . In a study comparing FeNO and sputum cell counts with serial spirometry and peak flow recordings in children and adults, the sensitivity of spirometry was lower (47 %) than that of either FeNO (88 %) or sputum induction (86 %) [32, 36] . In addition, FeNO and sputum eosinophils showed a specificity of 92 % compared with 73 % for spirometry [32, 36] .
Given that FeNO is representative of Th2-driven local inflammation specifically in the bronchial mucosa [32, [37] [38] [39] , it has the potential to predict the response to ICS therapy in asthma [3, [40] [41] [42] [43] [44] [45] [46] . Data suggest that asthma patients who have elevated baseline FeNO levels are more likely to respond to ICS than those with baseline FeNO levels within predefined normal ranges [32, 40, 41, 47] . However, there is conflicting evidence: in a study by Klaassen et al., symptoms not FeNO levels predicted response to ICS [48] , and Prieto et al. showed that FeNO was not useful in predicting response above a baseline cut-off of 20 ppb [49] . However, in the first study, FeNO was measured using an offline tidal breathing method rather than the recommended online measurement [48] .
FeNO is of particular interest for diagnosing and phenotyping asthma in children with suspected asthma, therefore enabling optimal treatment and control ( Fig. 4 ; Table 5 ).
Diagnosing asthma in children, particularly pre-schoolers, can be challenging. The advantage of FeNO is that, unlike other assessments, it does not involve a forced vital capacity maneuver, which makes it easier for children, and especially young children, to perform, therefore aiding cooperation [50] . Furthermore, the measurements are easy, quick to perform in the clinic and suggest that symptoms and exacerbations are not related to the same physiological mechanisms, with one more strongly related to airway inflammation and one more strongly related to bronchoconstriction [64] .
High FeNO levels in ICS-treated patients usually suggest uncontrolled asthma with high FeNO being correlated with high use of short-acting beta-agonists and oral corticosteroids as well as lower predicted FEV 1 levels during the preceding year compared to patients with low FeNO values [65] . In the follow-up study, high FeNO was shown to predict future uncontrolled asthma in patients treated with ICS; by adding FeNO to an asthma control questionnaire and spirometry during routine visits, patients likely to suffer exacerbations could be identified [66] . Negative studies on the use of FeNO for asthma management have been reported [32, [67] [68] [69] [70] . Use of FeNO was not recommended to tailor ICS treatment when compared to managing treatment based on clinical symptoms alone in a meta-analysis in 2009 [70] . However, this meta-analysis did not include many of the most recent studies that demonstrated a decrease in exacerbations, these studies were small, the majority of subjects had mild-to-moderate asthma, and the means of measuring outcomes varied. Indeed, a newer meta-analysis of these data with the addition of newer studies showed the rate of exacerbations to be significantly lower in FeNO-guided children compared with the control group [27] . This result was confirmed recently in a further meta-analysis in children [71] .
Combining the results of six eligible studies involving children, the odds ratio of exacerbation was significantly lower in the Optimum ICS dosing is important for ensuring patient safety while maintaining adequate asthma control [32] . However, in order to obtain these benefits, ICS must be taken regularly, and many studies have shown that treatment compliance among patients with asthma is frequently poor, which leads to loss of control and increased morbidity [74] . Reliably identifying non-compliance could be valuable in improving the understanding of factors contributing to on-going symptoms in asthma [29, 74] .
Increased FeNO levels ([25 ppb) in children prescribed ICS was associated with reduced treatment adherence (OR 0.25, 95 % CI 0.15-0.41) [32, 75] , and improved ICS adherence correlated with a greater reduction in FeNO in patients with difficult-to-treat asthma [29, 32] . Another study found serial FeNO measurements helped to determine treatment adherence and showed that adherence with ICS was significantly associated (p\0.001) with a fall in FeNO over the study period [12, 22] . Although elevated FeNO levels may reflect poorer adherence, confounding factors such as disease activity and inhaler technique need to be carefully considered [74] . It is not unusual, in my clinical experience, to see an increase in FeNO accompanied by a 'loss of optimal inhaler technique' in many children and young adults. This is often a complete surprise to parents, particularly when they find that the use of large-volume spacers has been abandoned or that other important steps in inhaler use are being omitted.
Cost-Effectiveness and Recent NICE Recommendations
FeNO is a useful tool for targeting those patients who will benefit from anti-inflammatory treatment [76] . In difficult, poorly controlled asthma, when symptoms may have multiple causes, FeNO may be used to monitor treatment to avoid unnecessary increases in steroid therapy [76, 77] . This is particularly important in light of financial constraints in healthcare especially given the large cost implication of ineffective treatments. FeNO measurements offer the potential to reduce costs while simultaneously improving the quality of patient care with more accurate phenotypic assessment and precision treatment [76] .
In the US, 30 % of asthma patients have severe or difficult-to-treat asthma, achieve suboptimal control and show relative non-responsiveness to medication. It is estimated that this relatively small proportion of patients accounts for 80 % of asthma medical costs [31] . Adding FeNO to standard asthma management offers potential cost savings. The inclusion of FeNO measurements may ensure parity was reached with the current standard of care in the US, assuming a reduction of 5 % in hospitalization and emergency department costs; this is despite the costs of performing the FeNO tests [31] .
The cost effectiveness of FeNO was investigated in a German study [30] have is a hammer then everything looks like a nail' [78] . Thus, for clinicians there is a temptation to label everything that wheezes as asthma as treatments are both available and of proven efficacy. Pre-school wheeze is a common problem, affecting up to a third of all children [79, 80] . The disappointing results from recent randomized controlled studies in this group of children have highlighted the lack of evidence for any effective treatments in an unrefined population of early-onset wheezers [81, 82] .
There is an urgent need for improved identification of endotypes in young wheezy children, particularly those who present acutely and recurrently to hospital with viral-induced wheeze.
Current treatment strategies broadly separate children into two distinct groups: those with episodic viral symptoms or those with multiple triggers [79, 80] . In clinical practice, intuition and experience are required as parental report alone is often misleading [83] . Despite a paucity of evidence, children with recurrent symptoms are often treated speculatively with either increasing doses of ICS or LTRA. FeNO discriminates between different subtypes of wheeze and predicts the likely natural history [84, 85] . Studies are now required to determine whether FeNO plus clinical parameters can be used to predict response (or non-response) to any treatment.
Longitudinal Measurement of FeNO and Home Measurement
Studies in which longitudinal measures of FeNO have been used to drive clinical decisions have not been wholly successful in either adults or children [32] . This is probably due to a number of factors including differences in study design, sample size, methodology, the application of different FeNO algorithms and devices, and inconsistencies in predefined study endpoints. The desire to define a single value upon which treatment decisions are based is almost certainly a big limitation and works contrary to everything that is known about personalized medicine.
The 
